A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this open-label study regimen is to make didanosine (ddI) available to
patients with AIDS who are clinically deteriorating on zidovudine (AZT) and cannot enter the
Phase II ddI programs due to protocol exclusion or geographic location.